
Figure S2: Site-specific O-GlcNAc-CRMP2 antibody (OG-CRMP2) recognises Ser517 O-GlcNAcylated CRMP2 in vitro and in vivo. (a) Western blot on in vitro glycosylated recombinant CRMP2 using the OG-CRMP2 antibody. Lack of signal on non-O-GlcNAcylated and Ser517Ala CRMP2 samples indicates that the antibody is specific. (b) Western blot on mouse brain lysate using the OG-CRMP2 antibody showing that the antibody detects O-GlcNAcylated CRMP2 from complex samples. CpOGA treatment removes O-GlcNAc from proteins and the Ser517Ala mutation abolishes O-GlcNAcylation on CRMP2.Supplementary Figure S3: O-GlcNAc-CRMP2 levels in samples from Alzheimer's disease patients. (a) Western blotting for O-GlcNAc-CRMP2 (OG-CRMP2) on post-mortem hippocampus samples from Alzheimer's disease patients (AD) and age-matched non-Alzheimer's disease individuals (CTL) (n = 5, 75-80 years old).
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 0 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
